pcmr12037-sup-0010-DataS1.docWord document49KData S1. Materials and Methods.
pcmr12037-sup-0001-FigS1.epsimage/eps20750KFigure S1. Representative immunohistochemistry images with DAB staining of NAMPT in nodular melanoma (A), superficial spreading melanoma (B), lung metastasis of melanoma (C), junctional nevus (D), Spitz nevus (E) and intradermal papillomatous nevus (F).
pcmr12037-sup-0002-FigS2.epsimage/eps4539KFigure S2. (A) Quantification of NAMPT expression using Quantity one software; data were from 4 separate experiments; (B) representative immunofluorescence images of NAMPT localization in MeWo and HMCB cells; (C) Immunoblotting of NAMPT in the cytosolic and nuclear fractions of MeWo and HMCB cells.
pcmr12037-sup-0003-FigS3.epsimage/eps892KFigure S3. Viability assay of MeWo (A) and HMCB (B) cells after 72 and 96 h of treatment with FK866.
pcmr12037-sup-0004-FigS4.epsimage/eps1088KFigure S4. Viability assay of HMCB (A), MeWo (B) and SK-Mel-28 (C) cells at different concentrations after 48 h of treatment with FK866.
pcmr12037-sup-0005-FigS5.epsimage/eps2183KFigure S5. Determination of NAD levels after 32 h of treatment in LB-24, SK-Mel-28 and WM-115 cells.
pcmr12037-sup-0006-FigS6.epsimage/eps344KFigure S6. Viability assay of MeWo (C, D) and HMCB (A, B) cells after 48 h of treatment with FK866 alone or in combination with temozolomide or dacarbazine at the indicated concentrations.
pcmr12037-sup-0007-TableS1.epsimage/eps1832KTable S1. Synopsis of melanocytic lesions investigated via immunocytochemistry.
pcmr12037-sup-0008-TableS2.epsimage/eps451KTable S2. anti-NAMPT immunocytochemistry evaluation of melanocytic lesions.
pcmr12037-sup-0009-Supplementary-figures-legend.docWord document28K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.